Ruan Guo-Tian, Deng Li, Xie Hai-Lun, Shi Jin-Yu, Liu Xiao-Yue, Zheng Xin, Chen Yue, Lin Shi-Qi, Zhang He-Yang, Liu Chen-An, Ge Yi-Zhong, Song Meng-Meng, Hu Chun-Lei, Zhang Xiao-Wei, Yang Ming, Hu Wen, Cong Ming-Hua, Zhu Li-Chen, Wang Kun-Hua, Shi Han-Ping
Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, 10 Tie Yi Road, Beijing, 100038, China.
National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, 10 Tie Yi Road, Beijing, 100053, China.
Cancer Metab. 2024 Jan 25;12(1):3. doi: 10.1186/s40170-024-00332-8.
The C-reactive protein (CRP)-triglyceride-glucose (TyG) index (CTI), which is a measure representing the level of inflammation and insulin resistance (IR), is related to poor cancer prognosis; however, the CTI has not been validated in patients with cancer cachexia. Thus, this study aimed to explore the potential clinical value of the CTI in patients with cancer cachexia.
In this study, our prospective multicenter cohort included 1411 patients with cancer cachexia (mean age 59.45 ± 11.38, 63.3% male), which was a combined analysis of multiple cancer types. We randomly selected 30% of the patients for the internal test cohort (mean age 58.90 ± 11.22% 61.4% male). Additionally, we included 307 patients with cancer cachexia in the external validation cohort (mean age 61.16 ± 11, 58.5% male). Receiver operating characteristic (ROC) and calibration curves were performed to investigate the prognostic value of CTI. The prognostic value of the CTI was also investigated performing univariate and multivariate survival analyses.
The survival curve indicated that the CTI showed a significant prognostic value in the total, internal, and external validation cohorts. Prognostic ROC curves and calibration curves revealed that the CTI showed good consistency in predicting the survival of patients with cancer cachexia. Multivariate survival analysis showed that an elevated CTI increased the risk of death by 22% (total cohort, 95% confidence interval [CI] = 1.13-1.33), 34% (internal test cohort, 95%CI = 1.11-1.62), and 35% (external validation cohort, 95%CI = 1.14-1.59) for each increase in the standard deviation of CTI. High CTI reliably predicted shorter survival (total cohort, hazard ratio [HR] = 1.45, 95%CI = 1.22-1.71; internal test cohort, HR = 1.62, 95%CI = 1.12-2.36; external validation cohort, HR = 1.61, 95%CI = 1.15-2.26). High CTI significantly predicted shorter survival in different tumor subgroups, such as esophageal [HR = 2.11, 95%CI = 1.05-4.21] and colorectal cancer [HR = 2.29, 95%CI = 1.42-3.71]. The mediating effects analysis found that the mediating proportions of PGSGA, ECOG PS, and EORTC QLQ-C30 on the direct effects of CTI were 21.72%, 19.63%, and 11.61%, respectively We found that there was a significant positive correlation between the CTI and 90-day [HR = 2.48, 95%CI = 1.52-4.14] and 180-day mortality [HR = 1.77,95%CI = 1.24-2.55] in patients with cancer cachexia.
The CTI can predict the short- and long-term survival of patients with cancer cachexia and provide a useful prognostic tool for clinical practice.
C反应蛋白(CRP)-甘油三酯-葡萄糖(TyG)指数(CTI)是一种反映炎症水平和胰岛素抵抗(IR)的指标,与癌症预后不良相关;然而,CTI在癌症恶病质患者中尚未得到验证。因此,本研究旨在探讨CTI在癌症恶病质患者中的潜在临床价值。
在本研究中,我们的前瞻性多中心队列包括1411例癌症恶病质患者(平均年龄59.45±11.38岁,男性占63.3%),这是对多种癌症类型的综合分析。我们随机选择30%的患者作为内部测试队列(平均年龄58.90±11.22岁,男性占61.4%)。此外,我们在外部验证队列中纳入了307例癌症恶病质患者(平均年龄61.16±11岁,男性占58.5%)。绘制受试者工作特征(ROC)曲线和校准曲线以研究CTI的预后价值。还通过单因素和多因素生存分析研究了CTI的预后价值。
生存曲线表明,CTI在总队列、内部队列和外部验证队列中均显示出显著的预后价值。预后ROC曲线和校准曲线显示,CTI在预测癌症恶病质患者的生存方面具有良好的一致性。多因素生存分析表明,CTI每增加一个标准差,死亡风险分别增加22%(总队列,95%置信区间[CI]=1.13-1.33)、34%(内部测试队列,95%CI=1.11-1.62)和35%(外部验证队列,95%CI=1.14-1.59)。高CTI可靠地预测生存期较短(总队列,风险比[HR]=1.45,95%CI=1.22-1.71;内部测试队列,HR=1.62,95%CI=1.12-2.36;外部验证队列,HR=1.61,95%CI=1.15-2.26)。高CTI在不同肿瘤亚组中显著预测生存期较短,如食管癌[HR=2.11,95%CI=1.05-4.21]和结直肠癌[HR=2.29,95%CI=1.42-3.71]。中介效应分析发现,PGSGA、ECOG PS和EORTC QLQ-C30对CTI直接效应的中介比例分别为21.72%、19.63%和11.61%。我们发现,癌症恶病质患者的CTI与90天[HR=2.48,95%CI=1.52-4.14]和180天死亡率[HR=1.77,95%CI=1.24-2.55]之间存在显著正相关。
CTI可以预测癌症恶病质患者的短期和长期生存,并为临床实践提供一种有用的预后工具。